Medpace (NASDAQ:MEDP) Posts Quarterly Earnings Results, Beats Expectations By $0.71 EPS

Medpace (NASDAQ:MEDP) issued its quarterly earnings data on Monday. The company reported $3.67 earnings per share for the quarter, topping the consensus estimate of $2.96 by $0.71, Zacks reports. Medpace had a net margin of 17.66% and a return on equity of 50.87%. Medpace updated its FY 2025 guidance to 11.930-12.690 EPS.

Medpace Trading Down 7.5 %

NASDAQ:MEDP opened at $327.86 on Wednesday. The stock has a 50-day moving average price of $344.13 and a 200 day moving average price of $349.34. The stock has a market capitalization of $10.19 billion, a P/E ratio of 28.71, a P/E/G ratio of 1.85 and a beta of 1.36. Medpace has a 12-month low of $302.01 and a 12-month high of $459.77.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on MEDP shares. TD Cowen dropped their price target on shares of Medpace from $413.00 to $372.00 and set a “buy” rating on the stock in a research note on Wednesday, October 23rd. Baird R W cut Medpace from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 23rd. William Blair reissued an “outperform” rating on shares of Medpace in a report on Tuesday, October 22nd. Finally, Robert W. Baird upped their price target on Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research report on Monday, January 27th. Seven analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, Medpace presently has an average rating of “Hold” and a consensus target price of $381.44.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.